Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025)

NewAmsterdam Pharma (NAMS) has disclosed Other Operating Expenses for 1 consecutive years, with -$1000.0 as the latest value for Q3 2025.

  • Quarterly Other Operating Expenses changed N/A to -$1000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $61.8 million for FY2022, N/A changed from the prior year.
  • Other Operating Expenses hit -$1000.0 in Q3 2025 for NewAmsterdam Pharma.
  • In the past five years, Other Operating Expenses ranged from a high of -$1000.0 in Q3 2025 to a low of -$1000.0 in Q3 2025.